Clinical Trial Update: First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia [Phase 1, Phase 2]

View source ↗

Summary

First-in-human evaluation of an EAAT2-targeted PET tracer for imaging dementia, currently in Phase 1/2 and recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia
• Frontotemporal Dementia

Drugs mentioned

• EAAT2 PET tracer

Snippet

Sponsor: David Wilson | Conditions: Alzheimer Disease, Frontotemporal Dementia | Phase 1, Phase 2 | Status: RECRUITING